Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
Leerink Partners Global BioPharma Conference
Date: | March 12, 2024 |
Time: | 10:40am ET |
Venue: | Fontainebleau Hotel |
Format: | Live presentation and webcast |
Webcast Link: | |
Information: | |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-leerink-global-biopharma-conference-302079499.html
SOURCE Chemomab Therapeutics Ltd
